| Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.Ren Fail | Pooled analysis | 2026 |
| GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.Drugs | Pooled analysis | 2026 |
| Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.Schizophr Res | Pooled analysis | 2026 |
| Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis.Eur J Clin Pharmacol | Pooled analysis | 2026 |
| Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis.Medicine (Baltimore) | Pooled analysis | 2026 |
| CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2026 |
| Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.J Psychopharmacol | Pooled analysis | 2026 |
| GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.Drugs | Pooled analysis | 2026 |
| Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.Clin Obes | Pooled analysis | 2026 |
| Glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.Headache | Pooled analysis | 2026 |
| Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.Clin Obes | Pooled analysis | 2026 |
| Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.J Endocrinol Invest | Pooled analysis | 2026 |
| Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.PeerJ | Pooled analysis | 2026 |
| Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.Endocrinol Diabetes Metab | Pooled analysis | 2026 |
| Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.JAMA Psychiatry | Pooled analysis | 2026 |
| Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles.Pharmacol Res | Pooled analysis | 2026 |
| Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.Am J Cardiol | Pooled analysis | 2026 |
| Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis.JAMA Pediatr | Pooled analysis | 2026 |
| Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Diabetes Obes Metab | Pooled analysis | 2026 |
| Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis.Graefes Arch Clin Exp Ophthalmol | Pooled analysis | 2026 |
| Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.Clin Res Cardiol | Pooled analysis | 2026 |
| Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2026 |
| Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.Endocrine | Pooled analysis | 2026 |
| Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.J Clin Pharmacol | Pooled analysis | 2026 |
| Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs).Int J Obes (Lond) | Pooled analysis | 2026 |
| Weight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis.Clin Obes | Pooled analysis | 2026 |
| Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.Ann Intern Med | Pooled analysis | 2026 |
| Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis.Br J Clin Pharmacol | Pooled analysis | 2026 |
| Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations.Surg Endosc | Pooled analysis | 2026 |
| The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.Diabetes Obes Metab | Pooled analysis | 2026 |
| GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.Int J Obes (Lond) | Pooled analysis | 2026 |
| Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials.Can J Diabetes | Pooled analysis | 2026 |
| A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition.Obes Rev | Pooled analysis | 2026 |
| Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.Medicine (Baltimore) | Pooled analysis | 2026 |
| Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.Endocrine | Pooled analysis | 2026 |
| Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.Medicine (Baltimore) | Pooled analysis | 2026 |
| Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.Transl Psychiatry | Pooled analysis | 2026 |
| Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.BMJ | Pooled analysis | 2026 |
| Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.Diabetes Metab Syndr | Pooled analysis | 2026 |
| Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.J Int Med Res | Pooled analysis | 2026 |
| Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.Clin Ter | Pooled analysis | 2026 |
| Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.Endocrinol Diabetes Metab | Pooled analysis | 2026 |
| Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis.Diabetes Res Clin Pract | Pooled analysis | 2026 |
| Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.Diabetes Obes Metab | Pooled analysis | 2026 |
| Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis.BMC Ophthalmol | Pooled analysis | 2026 |
| Long-term effects of weight-reducing drugs in people with hypertension.Cochrane Database Syst Rev | Pooled analysis | 2026 |
| Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.Obesity (Silver Spring) | Pooled analysis | 2026 |
| Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Diabetes Obes Metab | Pooled analysis | 2026 |
| GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.Diabetes Obes Metab | Pooled analysis | 2026 |
| Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.Dis Mon | Pooled analysis | 2026 |
| Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.Diabetes Obes Metab | Pooled analysis | 2026 |
| Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.Ophthalmology | Pooled analysis | 2026 |
| Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.Expert Opin Drug Saf | Pooled analysis | 2026 |
| GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.Nutrients | Pooled analysis | 2026 |
| Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.Neurology | Pooled analysis | 2026 |
| Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis.Cardiovasc Diabetol | Pooled analysis | 2026 |
| Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.PLoS Med | Pooled analysis | 2026 |
| Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis.BMC Pharmacol Toxicol | Pooled analysis | 2026 |
| CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.Am J Cardiol | Pooled analysis | 2026 |
| Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.Endocrinol Diabetes Metab | Pooled analysis | 2026 |
| Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.Expert Rev Endocrinol Metab | Pooled analysis | 2026 |
| Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Hum Psychopharmacol | Pooled analysis | 2026 |
| Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.Adv Ther | Pooled analysis | 2026 |
| Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.Diabetes Obes Metab | Pooled analysis | 2026 |
| Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.JAMA Intern Med | Pooled analysis | 2026 |
| Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.Diabetes Obes Metab | Pooled analysis | 2026 |
| Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials.Int J Psychiatry Med | Pooled analysis | 2026 |
| Efficacy and safety of once-weekly insulins in type 2 diabetes: A systematic review and meta-analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss: A Systematic Review and Meta-Analysis.Ophthalmology | Pooled analysis | 2026 |
| Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis.Clin Ther | Pooled analysis | 2026 |
| Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution.Aliment Pharmacol Ther | Pooled analysis | 2026 |
| GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.Diabetes Obes Metab | Pooled analysis | 2026 |
| Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.Surg Obes Relat Dis | Pooled analysis | 2026 |
| Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 55 clinical trials.J Psychopharmacol | Pooled analysis | 2026 |
| Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.Endocr Pract | Pooled analysis | 2026 |
| Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2026 |
| Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials.BMC Endocr Disord | Pooled analysis | 2026 |
| GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.BMC Cardiovasc Disord | Pooled analysis | 2026 |
| Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials.Cell Rep Med | Pooled analysis | 2026 |
| Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials.Int J Mol Sci | Pooled analysis | 2026 |
| GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.Medicine (Baltimore) | Pooled analysis | 2026 |
| Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity.ESC Heart Fail | Pooled analysis | 2026 |
| Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.Obes Res Clin Pract | Pooled analysis | 2026 |
| The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.Child Obes | Pooled analysis | 2026 |
| Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta-Analysis of Real-World Studies.Endocr Pract | Pooled analysis | 2026 |
| Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.BMC Med | Pooled analysis | 2026 |
| Efficacy and safety of semaglutide in non-diabetic adults with overweight or obesity: A meta-analysis of randomized controlled trials.Eur J Pharmacol | Pooled analysis | 2026 |
| Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials.Med | Pooled analysis | 2026 |
| Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis.Diabetes Metab Res Rev | Pooled analysis | 2026 |
| Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide.J Diabetes | Pooled analysis | 2026 |
| Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis.Obesity (Silver Spring) | Pooled analysis | 2026 |
| Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH).Diabetes Obes Metab | Pooled analysis | 2026 |
| GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.Diabetes Obes Metab | Pooled analysis | 2026 |
| Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.Ann Intern Med | Pooled analysis | 2026 |
| Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials.Endocrine | Pooled analysis | 2026 |
| Effectiveness of GLP-1 RAs in Restoring Normoglycemia in Patients With Prediabetes: An Updated Systematic Review and Meta-Analysis.Diabetes Metab Res Rev | Pooled analysis | 2026 |
| Glucagon-like peptide-1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta-analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.Diabetes Obes Metab | Pooled analysis | 2026 |
| Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.Diabetes Obes Metab | Pooled analysis | 2026 |
| Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials.Int J Surg | Pooled analysis | 2026 |
| Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.Asia Pac J Ophthalmol (Phila) | Pooled analysis | 2026 |
| Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis.Hepatology | Pooled analysis | 2026 |
| Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.Gynecol Endocrinol | Pooled analysis | 2025 |
| Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis.Pol Arch Intern Med | Pooled analysis | 2025 |
| Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis.Medicine (Baltimore) | Pooled analysis | 2025 |
| Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.Medicine (Baltimore) | Pooled analysis | 2025 |
| The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis.Addict Sci Clin Pract | Pooled analysis | 2025 |
| Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis.Obes Surg | Pooled analysis | 2025 |
| Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis.Int J Cardiol | Pooled analysis | 2025 |
| Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.Hepatology | Pooled analysis | 2025 |
| The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.BMC Med | Pooled analysis | 2025 |
| Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis.BMC Gastroenterol | Pooled analysis | 2025 |
| Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials.BMC Cardiovasc Disord | Pooled analysis | 2025 |
| Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.J Am Coll Cardiol | Pooled analysis | 2025 |
| [A meta-analysis of efficacy and safety of anti-obesity medications in the treatment of childhood obesity].Zhonghua Yi Xue Za Zhi | Pooled analysis | 2025 |
| Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis.J Crohns Colitis | Pooled analysis | 2025 |
| Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease.Eur J Med Res | Pooled analysis | 2025 |
| Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.Endocrinol Diabetes Metab | Pooled analysis | 2025 |
| Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials.Diabetes Obes Metab | Pooled analysis | 2025 |
| Plastic Surgery in the Ozempidemic: Considerations for the Timing of Body Contouring Surgery in Patients with Semaglutide-Associated Weight Loss.Aesthetic Plast Surg | Pooled analysis | 2025 |
| Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.Obesity (Silver Spring) | Pooled analysis | 2025 |
| GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials.Int J Cardiol | Pooled analysis | 2025 |
| Tirzepatide for adults living with obesity.Cochrane Database Syst Rev | Pooled analysis | 2025 |
| Liraglutide for adults living with obesity.Cochrane Database Syst Rev | Pooled analysis | 2025 |
| Semaglutide for adults living with obesity.Cochrane Database Syst Rev | Pooled analysis | 2025 |
| GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis.Langenbecks Arch Surg | Pooled analysis | 2025 |
| A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.Nat Med | Pooled analysis | 2025 |
| Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.Int J Obes (Lond) | Pooled analysis | 2025 |
| Quantitative analysis of the efficacy characteristics and influencing factors of weight loss drugs in children and adolescents.Diabetes Obes Metab | Pooled analysis | 2025 |
| Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.J Clin Endocrinol Metab | Pooled analysis | 2025 |
| Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials.Eur J Pharmacol | Pooled analysis | 2025 |
| Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis.Eur J Med Res | Pooled analysis | 2025 |
| Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Endocrinol Diabetes Metab | Pooled analysis | 2025 |
| Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials.J Diabetes | Pooled analysis | 2025 |
| Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.JAMA Ophthalmol | Pooled analysis | 2025 |
| Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials.Liver Int | Pooled analysis | 2025 |
| Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in China.Diabetes Obes Metab | Pooled analysis | 2025 |
| Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.Diabetes Obes Metab | Pooled analysis | 2025 |
| Comparative Effectiveness of Glucagon-like Peptide-1- Receptor Agonists in Patients With Heart Failure With Preserved or Minimally Reduced Ejection Fraction: A Comprehensive Bayesian Network Meta-Analysis and Network Meta-Regression.Endocr Pract | Pooled analysis | 2025 |
| Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.Am J Cardiovasc Drugs | Pooled analysis | 2025 |
| Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.Acta Diabetol | Pooled analysis | 2025 |
| Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis.Int J Obes (Lond) | Pooled analysis | 2025 |
| Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2025 |
| Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis.Surg Endosc | Pooled analysis | 2025 |
| GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.Diabetes Obes Metab | Pooled analysis | 2025 |
| Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.Clin Obes | Pooled analysis | 2025 |
| Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.Obes Rev | Pooled analysis | 2025 |
| Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.J Obes | Pooled analysis | 2025 |
| The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials.BMC Endocr Disord | Pooled analysis | 2025 |
| Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis.Sci Rep | Pooled analysis | 2025 |
| Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.Obes Surg | Pooled analysis | 2025 |
| Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.Diabetes Obes Metab | Pooled analysis | 2025 |
| Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.Am J Cardiovasc Drugs | Pooled analysis | 2025 |
| Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.Am J Cardiovasc Drugs | Pooled analysis | 2025 |
| Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs.Front Endocrinol (Lausanne) | Pooled analysis | 2025 |
| Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.Diabetes Care | Pooled analysis | 2025 |
| Comparative efficacy and safety of antidiabetic drugs for obese patients with knee osteoarthritis: a network meta-analysis of randomized controlled trials.Aging Clin Exp Res | Pooled analysis | 2025 |
| Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.Horm Metab Res | Pooled analysis | 2025 |
| Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.Obes Surg | Pooled analysis | 2025 |
| Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.Endocrinol Diabetes Metab | Pooled analysis | 2025 |
| Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.Diabetes Care | Pooled analysis | 2025 |
| Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.J Diabetes | Pooled analysis | 2025 |
| Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.Diabetes Obes Metab | Pooled analysis | 2025 |
| Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis.Clin Nutr ESPEN | Pooled analysis | 2025 |
| Efficacy of Oral Medication in Weight Loss Management: A Systematic Review and Network Meta-Analysis.Clin Ther | Pooled analysis | 2025 |
| A meta-analysis on the risk of esophageal cancer in type 2 diabetes patients treated with GLP-1 receptor agonists.Front Endocrinol (Lausanne) | Pooled analysis | 2025 |
| Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.Ann Saudi Med | Pooled analysis | 2025 |
| Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.J Diabetes | Pooled analysis | 2025 |
| Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.Obes Surg | Pooled analysis | 2025 |
| Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.Metabolism | Pooled analysis | 2025 |
| Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis.PLoS One | Pooled analysis | 2025 |
| Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.Clin Transl Sci | Pooled analysis | 2025 |
| The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.J Endocrinol Invest | Pooled analysis | 2025 |
| Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials.Curr Med Res Opin | Pooled analysis | 2025 |
| Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.Int J Obes (Lond) | Pooled analysis | 2025 |
| Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.Clin Pharmacokinet | Pooled analysis | 2024 |
| Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis.Epilepsia Open | Pooled analysis | 2024 |
| Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.Metabolism | Pooled analysis | 2024 |
| Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.Eur J Clin Invest | Pooled analysis | 2024 |
| Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline.Pediatr Obes | Pooled analysis | 2024 |
| Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis.Obes Rev | Pooled analysis | 2024 |
| Semaglutide and blood pressure: an individual patient data meta-analysis.Eur Heart J | Pooled analysis | 2024 |
| The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials.J Diabetes Complications | Pooled analysis | 2024 |
| Medication adherence to sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists: A meta-analysis.Diabetes Obes Metab | Pooled analysis | 2024 |
| Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.Diabetes Obes Metab | Pooled analysis | 2024 |
| Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis.J Clin Pharmacol | Pooled analysis | 2024 |
| Evaluating the safety profile of semaglutide: an updated meta-analysis.Curr Med Res Opin | Pooled analysis | 2024 |
| Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials.Obes Rev | Pooled analysis | 2024 |
| Semaglutide and heart failure: Updated meta-analysis.Curr Probl Cardiol | Pooled analysis | 2024 |
| Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment.J Clin Endocrinol Metab | Pooled analysis | 2024 |
| Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Am J Cardiol | Pooled analysis | 2024 |
| Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.Diabetologia | Pooled analysis | 2024 |
| Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis.Diabetes Metab Syndr | Pooled analysis | 2024 |
| Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.Exp Clin Endocrinol Diabetes | Pooled analysis | 2024 |
| Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.Diabetes Obes Metab | Pooled analysis | 2024 |
| Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis.Medicine (Baltimore) | Pooled analysis | 2024 |
| Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.Obes Surg | Pooled analysis | 2024 |
| Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.Obes Rev | Pooled analysis | 2024 |
| Pharmacological interventions for the management of children and adolescents living with obesity-An update of a Cochrane systematic review with meta-analyses.Pediatr Obes | Pooled analysis | 2024 |
| The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines.J Endocrinol | Pooled analysis | 2024 |
| Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline.Obes Rev | Pooled analysis | 2024 |
| Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.Lancet | Pooled analysis | 2024 |
| Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.Thyroid | Pooled analysis | 2024 |
| Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis.Endocrinol Diabetes Nutr (Engl Ed) | Pooled analysis | 2024 |
| Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis.Diabetes Obes Metab | Pooled analysis | 2024 |
| The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.Endocrine | Pooled analysis | 2024 |
| Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.Diabetes Obes Metab | Pooled analysis | 2024 |
| A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.Medicina (Kaunas) | Pooled analysis | 2024 |
| Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.Biomed Pharmacother | Pooled analysis | 2024 |
| Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.Endocr Pract | Pooled analysis | 2024 |
| Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.BMJ | Pooled analysis | 2024 |
| Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.Pharmacol Res | Pooled analysis | 2024 |
| Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.Diabetes Obes Metab | Pooled analysis | 2024 |
| Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity.Eur J Prev Cardiol | Pooled analysis | 2023 |
| Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.Diabetes Obes Metab | Pooled analysis | 2023 |
| Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2023 |
| Efficacy and safety of semaglutide in non-alcoholic fatty liver disease.World J Gastroenterol | Pooled analysis | 2023 |
| Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.Diabetes Metab Syndr | Pooled analysis | 2023 |
| Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.Front Public Health | Pooled analysis | 2023 |
| The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.Am J Clin Nutr | Pooled analysis | 2023 |
| Semaglutide and cancer: A systematic review and meta-analysis.Diabetes Metab Syndr | Pooled analysis | 2023 |
| Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials.Diabetes Obes Metab | Pooled analysis | 2023 |
| Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.Front Endocrinol (Lausanne) | Pooled analysis | 2023 |
| Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.Clin Ther | Pooled analysis | 2023 |
| Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials.J Diabetes Complications | Pooled analysis | 2023 |
| Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.Int J Obes (Lond) | Pooled analysis | 2023 |
| Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review.Intern Med J | Pooled analysis | 2023 |
| Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.Medicine (Baltimore) | Pooled analysis | 2023 |
| GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2023 |
| Pharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysis.Clin Ther | Pooled analysis | 2023 |
| Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.Front Endocrinol (Lausanne) | Pooled analysis | 2023 |
| GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.J Clin Endocrinol Metab | Pooled analysis | 2023 |
| Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2023 |
| Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.Diabetes Res Clin Pract | Pooled analysis | 2023 |
| The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta-analysis of randomized controlled trials.Obes Rev | Pooled analysis | 2023 |
| Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk.Int J Mol Sci | Pooled analysis | 2023 |
| Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.BMJ Open | Pooled analysis | 2023 |
| Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.Obes Rev | Pooled analysis | 2023 |
| Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.Ann Med | Pooled analysis | 2023 |
| Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?Diabetes Metab Syndr | Pooled analysis | 2023 |
| Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.Eur J Gastroenterol Hepatol | Pooled analysis | 2023 |
| Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.Eur J Gastroenterol Hepatol | Pooled analysis | 2023 |
| Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis.Nutr Metab Cardiovasc Dis | Pooled analysis | 2022 |
| Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.J Diabetes Complications | Pooled analysis | 2022 |
| Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis.Int J Clin Pharm | Pooled analysis | 2022 |
| The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.Horm Metab Res | Pooled analysis | 2022 |
| Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis.Diabetes Metab Syndr | Pooled analysis | 2022 |
| Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.Diabetes Metab Syndr | Pooled analysis | 2022 |
| Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.Obes Rev | Pooled analysis | 2022 |
| Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.BMC Endocr Disord | Pooled analysis | 2022 |
| Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.Cardiovasc Diabetol | Pooled analysis | 2022 |
| An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression.J Clin Endocrinol Metab | Pooled analysis | 2022 |
| Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.Endocrine | Pooled analysis | 2022 |
| Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.LancetRetracted | Pooled analysis | 2022 |
| Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.J ASEAN Fed Endocr Soc | Pooled analysis | 2022 |
| Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.Clin Drug Investig | Pooled analysis | 2022 |
| Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.Clin Ther | Pooled analysis | 2021 |
| Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2021 |
| Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.Aliment Pharmacol Ther | Pooled analysis | 2021 |
| GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.Cardiovasc Diabetol | Pooled analysis | 2021 |
| Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.Diabetes Obes Metab | Pooled analysis | 2021 |
| Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.Medicine (Baltimore) | Pooled analysis | 2021 |
| Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis.Diabetes Res Clin Pract | Pooled analysis | 2021 |
| Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials.Endocr J | Pooled analysis | 2021 |
| Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.Prim Care Diabetes | Pooled analysis | 2021 |
| Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes.J Clin Endocrinol Metab | Pooled analysis | 2021 |
| Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.Diabetes Res Clin Pract | Pooled analysis | 2021 |
| Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.J Cardiovasc Pharmacol | Pooled analysis | 2021 |
| Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.Diabetes Obes Metab | Pooled analysis | 2021 |
| Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus.Curr Diabetes Rev | Pooled analysis | 2021 |
| Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.J Clin Endocrinol Metab | Pooled analysis | 2020 |
| Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.Ann Intern Med | Pooled analysis | 2020 |
| Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.Diabetes Obes Metab | Pooled analysis | 2020 |
| Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.Nutr Metab Cardiovasc Dis | Pooled analysis | 2020 |
| Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.Cardiovasc Diabetol | Pooled analysis | 2020 |
| Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map.Lancet Diabetes Endocrinol | Pooled analysis | 2020 |
| Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.Diabetes Obes Metab | Pooled analysis | 2020 |
| Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.J Med Econ | Pooled analysis | 2020 |
| GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.Diabetes Obes Metab | Pooled analysis | 2019 |
| Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet Diabetes Endocrinol | Pooled analysis | 2019 |
| Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Acta Diabetol | Pooled analysis | 2019 |
| Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.Diabetes Metab J | Pooled analysis | 2019 |
| Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.BMJ Open | Pooled analysis | 2019 |
| Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.J Diabetes Res | Pooled analysis | 2019 |
| Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.Diabetes Metab | Pooled analysis | 2019 |
| The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.Endocrine | Pooled analysis | 2018 |
| Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.Osteoporos Int | Pooled analysis | 2018 |
| Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study.Diabetes Obes Metab | Random groups | 2026 |
| Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial.Diabetes Obes Metab | Random groups | 2026 |
| Semaglutide modulates explore/exploit decision-making in major depressive disorder: A randomized clinical trial.Psychol Med | Random groups | 2026 |
| Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial.J Diabetes Complications | Random groups | 2026 |
| Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial.Lancet Diabetes Endocrinol | Random groups | 2026 |
| Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.Lancet Diabetes Endocrinol | Random groups | 2026 |
| Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.Lancet Diabetes Endocrinol | Random groups | 2026 |
| Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials.Diabetes Obes Metab | Random groups | 2026 |
| Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).Diabetes Obes Metab | Random groups | 2026 |
| Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.Diabetes Obes Metab | Random groups | 2026 |
| Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.Diabetes Obes Metab | Random groups | 2026 |
| Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial.Indian J Gastroenterol | Random groups | 2026 |
| Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.Circulation | Random groups | 2026 |
| Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.Am J Psychiatry | Random groups | 2026 |
| Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.Lancet Gastroenterol Hepatol | Random groups | 2026 |
| Computational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss.Aesthetic Plast Surg | Random groups | 2026 |
| Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.Diabetes Obes Metab | Random groups | 2026 |
| Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.Diabetes Obes Metab | Random groups | 2026 |
| Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.Nephrol Dial Transplant | Random groups | 2026 |
| Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.Ann Intern Med | Random groups | 2026 |
| Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial.Am J Clin Nutr | Random groups | 2026 |
| A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.Aesthetic Plast Surg | Random groups | 2026 |
| Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.Lancet Diabetes Endocrinol | Random groups | 2026 |
| Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.Lancet Diabetes Endocrinol | Random groups | 2026 |
| Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.Diabetes Obes Metab | Random groups | 2026 |
| Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.Diabetes Obes Metab | Random groups | 2026 |
| Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial.Diabetes Obes Metab | Random groups | 2026 |
| Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.Lancet | Random groups | 2026 |
| Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial.Clin J Am Soc Nephrol | Random groups | 2026 |
| Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clin Pharmacokinet | Random groups | 2026 |
| Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.Nat Med | Random groups | 2026 |
| Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.Lancet Diabetes Endocrinol | Random groups | 2026 |
| Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.Pak J Pharm Sci | Random groups | 2026 |
| Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Nat Med | Random groups | 2026 |
| Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.JAMA Psychiatry | Random groups | 2026 |
| Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.Diabetes Obes Metab | Random groups | 2026 |
| Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.Am J Med | Random groups | 2026 |
| Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.Lancet | Random groups | 2026 |
| Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.J Am Coll Cardiol | Random groups | 2026 |
| Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population.J Am Coll Cardiol | Random groups | 2026 |
| Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.Curr Med Res Opin | Random groups | 2026 |
| Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.Lancet Diabetes Endocrinol | Random groups | 2026 |
| Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.Diabetes Care | Random groups | 2026 |
| Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet | Random groups | 2026 |
| Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial.Clin Infect Dis | Random groups | 2026 |
| Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.Nat Commun | Random groups | 2026 |
| Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.Lancet | Random groups | 2026 |
| Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.JAMA Netw Open | Random groups | 2026 |
| Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.Nat Med | Random groups | 2026 |
| Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.JAMA Cardiol | Random groups | 2026 |
| Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.Diabetes Care | Random groups | 2026 |
| Improved quality of life with semaglutide in schizophrenia: Secondary analyses from a randomized controlled trial.Schizophr Res | Random groups | 2026 |
| Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis.Diabetes Care | Random groups | 2026 |
| Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.Diabetologia | Random groups | 2026 |
| Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.JAMA Intern Med | Random groups | 2026 |
| Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA).Aliment Pharmacol Ther | Random groups | 2026 |
| Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.Metabolism | Random groups | 2026 |
| Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.Nat Commun | Random groups | 2026 |
| Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet | Random groups | 2026 |
| Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.Eur Heart J | Random groups | 2026 |
| [SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes].Rev Med Liege | Random groups | 2026 |
| Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.Nat Med | Random groups | 2026 |
| Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial.Pharmacoeconomics | Random groups | 2026 |
| Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.JAMA Cardiol | Random groups | 2026 |
| Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.Diabetes Care | Random groups | 2026 |
| Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.JAMA Psychiatry | Random groups | 2026 |
| CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.Hypertension | Random groups | 2026 |
| Semaglutide Use With Automated Insulin Delivery in Adults With Type 1 Diabetes: Qualitative Analyses and Patient-reported Outcomes From a Randomized Controlled Trial.Can J Diabetes | Random groups | 2026 |
| Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH.Aliment Pharmacol Ther | Random groups | 2026 |
| Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.Med | Random groups | 2026 |
| Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.Diabetes Obes Metab | Random groups | 2026 |
| Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial.Diabetes Obes Metab | Random groups | 2026 |
| Effects of Dichrostachys glomerata and Cissus quadrangularis Extracts on GLP-1 Secretion and DPP-4 Activity in Overweight and Obese Individuals: A Randomized Controlled Trial.Medicina (Kaunas) | Random groups | 2025 |
| Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.Cardiovasc Diabetol | Random groups | 2025 |
| Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.J Clin Endocrinol Metab | Random groups | 2025 |
| Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial.Nat Commun | Random groups | 2025 |
| Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study.Obes Surg | Random groups | 2025 |
| Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.J Am Coll Cardiol | Random groups | 2025 |
| Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.Lancet | Random groups | 2025 |
| Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.Eur J Heart Fail | Random groups | 2025 |
| In adults with obesity but without type 2 diabetes, tirzepatide increased weight loss at 72 wk compared with semaglutide.Ann Intern Med | Random groups | 2025 |
| Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.JACC Heart Fail | Random groups | 2025 |
| Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.Lancet Diabetes Endocrinol | Random groups | 2025 |
| Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.Lancet Diabetes Endocrinol | Random groups | 2025 |
| Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial.JAMA Psychiatry | Random groups | 2025 |
| Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.Diabetes Obes Metab | Random groups | 2025 |
| Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.Diabetes Care | Random groups | 2025 |
| Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.Am Heart J | Random groups | 2025 |
| Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial.BMJ Open Diabetes Res Care | Random groups | 2025 |
| Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.JACC Heart Fail | Random groups | 2025 |
| Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Diabetes Endocrinol | Random groups | 2025 |
| Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.JAMA Intern Med | Random groups | 2025 |
| Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.Diabetes Obes Metab | Random groups | 2025 |
| Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.N Engl J Med | Random groups | 2025 |
| Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.Diabetes Care | Random groups | 2025 |
| Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.Diabetes Care | Random groups | 2025 |
| Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.Diabetes Obes Metab | Random groups | 2025 |
| Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus.Br J Clin Pharmacol | Random groups | 2025 |
| The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial.Nutr Metab Cardiovasc Dis | Random groups | 2025 |
| Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.N Engl J Med | Random groups | 2025 |
| Long-acting PYY3 -36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies.Obesity (Silver Spring) | Random groups | 2025 |
| Semaglutide in Adults with Type 1 Diabetes and Obesity.NEJM Evid | Random groups | 2025 |
| Impact of weight on daily activities questionnaire in patients with overweight or obesity: Psychometric evaluation using data from the OASIS 1 trial.Clin Obes | Random groups | 2025 |
| Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial.Reprod Biol Endocrinol | Random groups | 2025 |
| Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J Med | Random groups | 2025 |
| Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia.Lancet Psychiatry | Random groups | 2025 |
| Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.Lancet Diabetes Endocrinol | Random groups | 2025 |
| Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.Lancet Diabetes Endocrinol | Random groups | 2025 |
| Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.Diabetes Obes Metab | Random groups | 2025 |
| Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study.Int J Mol Sci | Random groups | 2025 |
| Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.Circulation | Random groups | 2025 |
| Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.N Engl J Med | Random groups | 2025 |
| High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.Diabetes Care | Random groups | 2025 |
| Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial.J Diabetes Complications | Random groups | 2025 |
| Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.Diabetes Obes Metab | Random groups | 2025 |
| Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.N Engl J Med | Random groups | 2025 |
| The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers.J Basic Clin Physiol Pharmacol | Random groups | 2025 |
| Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.Lancet | Random groups | 2025 |
| Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.Diabetes Obes Metab | Random groups | 2025 |
| Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.JAMA Psychiatry | Random groups | 2025 |
| Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.Diabetologia | Random groups | 2025 |
| Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA.JACC Cardiovasc Imaging | Random groups | 2025 |
| Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.Nat Med | Random groups | 2025 |
| Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.Eur Heart J | Random groups | 2025 |
| Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial.Obes Res Clin Pract | Random groups | 2025 |
| Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.Obesity (Silver Spring) | Random groups | 2025 |
| Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.Lancet Diabetes Endocrinol | Random groups | 2025 |
| Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.Diabetes Obes Metab | Random groups | 2025 |
| Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.J Clin Endocrinol Metab | Random groups | 2025 |
| Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.Nephrol Dial Transplant | Random groups | 2025 |
| Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials.Obesity (Silver Spring) | Random groups | 2025 |
| Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.Diabetes Obes Metab | Random groups | 2025 |
| De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).Diabetes Obes Metab | Random groups | 2025 |
| Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.Diabetes Obes Metab | Random groups | 2025 |
| evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.Alzheimers Res Ther | Random groups | 2025 |
| Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial.Biomolecules | Random groups | 2025 |
| Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.Nat Med | Random groups | 2025 |
| Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.Clin Gastroenterol Hepatol | Random groups | 2025 |
| Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes Obes Metab | Random groups | 2024 |
| A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.Kidney Int | Random groups | 2024 |
| Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non-Japanese Participants.J Clin Pharmacol | Random groups | 2024 |
| Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.J Clin Endocrinol Metab | Random groups | 2024 |
| Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis.Obes Res Clin Pract | Random groups | 2024 |
| Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus.Clin Drug Investig | Random groups | 2024 |
| Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.Diabetes Obes Metab | Random groups | 2024 |
| Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.JAMA Intern Med | Random groups | 2024 |
| Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.Diabetes Obes Metab | Random groups | 2024 |
| Application of the integrated data platform combined with dietary management for adults with diabetes: A prospective randomized controlled trial.J Diabetes Investig | Random groups | 2024 |
| Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.N Engl J Med | Random groups | 2024 |
| Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.J Am Coll Cardiol | Random groups | 2024 |
| Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.J Am Coll Cardiol | Random groups | 2024 |
| Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.J Am Coll Cardiol | Random groups | 2024 |
| The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.J Am Coll Cardiol | Random groups | 2024 |
| Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.J Am Coll Cardiol | Random groups | 2024 |
| Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial.Diabetes Obes Metab | Random groups | 2024 |
| Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.Diabetologia | Random groups | 2024 |
| Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.Nat Med | Random groups | 2024 |
| Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.Eur Heart J | Random groups | 2024 |
| Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.Lancet | Random groups | 2024 |
| Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.Lancet Diabetes Endocrinol | Random groups | 2024 |
| Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.Diabetologia | Random groups | 2024 |
| Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.Diabetologia | Random groups | 2024 |
| Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.J Am Coll Cardiol | Random groups | 2024 |
| Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.Lancet | Random groups | 2024 |
| Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trial.Trials | Random groups | 2024 |
| Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.Medicine (Baltimore) | Random groups | 2024 |
| Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus.Clin Nutr | Random groups | 2024 |
| Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial.Lancet Diabetes Endocrinol | Random groups | 2024 |
| Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.Diabetes Care | Random groups | 2024 |
| Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.Diabetes Care | Random groups | 2024 |
| A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.Diabetes Obes Metab | Random groups | 2024 |
| Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.J Am Coll Cardiol | Random groups | 2024 |
| Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.N Engl J Med | Random groups | 2024 |
| Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.J Am Coll Cardiol | Random groups | 2024 |
| Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.Nat Med | Random groups | 2024 |
| Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.Nat Med | Random groups | 2024 |
| Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.Diabetes Obes Metab | Random groups | 2024 |
| Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis.Hepatology | Random groups | 2024 |
| Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series.J Spinal Cord Med | Random groups | 2024 |
| Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).J Clin Endocrinol Metab | Random groups | 2024 |
| Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.Diabetes Res Clin Pract | Random groups | 2024 |
| Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.Diabetes Care | Random groups | 2024 |
| Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.Clin Pharmacol Drug Dev | Random groups | 2024 |
| Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.Diabetes Obes Metab | Random groups | 2024 |
| Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.Lancet | Random groups | 2024 |
| Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.N Engl J Med | Random groups | 2024 |
| Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.Lancet Diabetes Endocrinol | Random groups | 2024 |
| Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.Diabetologia | Random groups | 2024 |
| Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).Diabetes Obes Metab | Random groups | 2024 |
| The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial.J Diabetes Complications | Random groups | 2024 |
| Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.Diabetes Obes Metab | Random groups | 2024 |
| Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.Nat Metab | Random groups | 2024 |
| Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study.Obes Surg | Random groups | 2024 |
| Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China.Diabetes Obes Metab | Random groups | 2024 |
| Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.Diabetes Obes Metab | Random groups | 2024 |
| A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea.Pharmacoepidemiol Drug Saf | Random groups | 2024 |
| Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.N Engl J Med | Random groups | 2023 |
| Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).Diabetes Obes Metab | Random groups | 2023 |
| Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial.Int J Obes (Lond) | Random groups | 2023 |
| Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes.J Clin Endocrinol Metab | Random groups | 2023 |
| A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.J Hepatol | Random groups | 2023 |
| Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.N Engl J Med | Random groups | 2023 |
| Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.Obesity (Silver Spring) | Random groups | 2023 |
| Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog.Mol Metab | Random groups | 2023 |
| Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.Lancet | Random groups | 2023 |
| Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | Random groups | 2023 |
| Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet | Random groups | 2023 |
| Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet | Random groups | 2023 |
| Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial.Aliment Pharmacol Ther | Random groups | 2023 |
| Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.Obesity (Silver Spring) | Random groups | 2023 |
| The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.Diabetes Obes Metab | Random groups | 2023 |
| Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial.Clin Obes | Random groups | 2023 |
| Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.Lancet Gastroenterol Hepatol | Random groups | 2023 |
| Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.J Diabetes Investig | Random groups | 2023 |
| Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).Diabetes Obes Metab | Random groups | 2023 |
| Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial.J Diabetes Complications | Random groups | 2023 |
| Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.Diabetes Care | Random groups | 2023 |
| Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.Diabetologia | Random groups | 2023 |
| Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects.Clin Pharmacokinet | Random groups | 2023 |
| Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial.Obesity (Silver Spring) | Random groups | 2023 |
| Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.Diabetes Obes Metab | Random groups | 2023 |
| Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity.Diabetes Obes Metab | Random groups | 2023 |
| Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.Obesity (Silver Spring) | Random groups | 2023 |
| Once-Weekly Semaglutide in Adolescents with Obesity.N Engl J Med | Random groups | 2022 |
| Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.Nat Med | Random groups | 2022 |
| Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.JAMA Netw Open | Random groups | 2022 |
| Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.Stroke | Random groups | 2022 |
| Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.Diabetes Obes Metab | Random groups | 2022 |
| Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.J Hepatol | Random groups | 2022 |
| [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].Rev Med Suisse | Random groups | 2022 |
| Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Diabetes Obes Metab | Random groups | 2022 |
| Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.Appl Health Econ Health Policy | Random groups | 2022 |
| Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.Lancet Diabetes Endocrinol | Random groups | 2022 |
| Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.J Diabetes Investig | Random groups | 2022 |
| Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.Lancet Diabetes Endocrinol | Random groups | 2022 |
| Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.Circulation | Random groups | 2022 |
| Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials.Diabetes Obes Metab | Random groups | 2022 |
| Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA | Random groups | 2022 |
| Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Diabetes Obes Metab | Random groups | 2022 |
| [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].Rev Med Liege | Random groups | 2021 |
| Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.Diabetes Obes Metab | Random groups | 2021 |
| Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.Aliment Pharmacol Ther | Random groups | 2021 |
| The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis.Hepatology | Random groups | 2021 |
| Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.Lancet Diabetes Endocrinol | Random groups | 2021 |
| Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med | Random groups | 2021 |
| Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.Diabetes Res Clin Pract | Random groups | 2021 |
| Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.Diabetes Obes Metab | Random groups | 2021 |
| Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.Diabetes Obes Metab | Random groups | 2021 |
| Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet | Random groups | 2021 |
| Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study.Clin Pharmacol Drug Dev | Random groups | 2021 |
| Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.JAMA | Random groups | 2021 |
| A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.N Engl J Med | Random groups | 2021 |
| Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial.J Diabetes Complications | Random groups | 2021 |
| The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.Diabetes Obes Metab | Random groups | 2021 |
| Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.Diabetes Obes Metab | Random groups | 2021 |
| Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.Diabetes Obes Metab | Random groups | 2021 |
| Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.Adv Ther | Random groups | 2021 |
| Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.BMJ Open Diabetes Res Care | Random groups | 2020 |
| Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.Lancet Diabetes Endocrinol | Random groups | 2020 |
| Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.Diabetes Obes Metab | Random groups | 2020 |
| The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.Diabetes Obes Metab | Random groups | 2020 |
| Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).Diabetes Obes Metab | Random groups | 2020 |
| Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.Obesity (Silver Spring) | Random groups | 2020 |
| Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.Lancet Diabetes Endocrinol | Random groups | 2020 |
| Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.Lancet Diabetes Endocrinol | Random groups | 2020 |
| Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?Expert Opin Biol Ther | Random groups | 2020 |
| Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).Diabetes Metab | Random groups | 2020 |
| Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.Diabetologia | Random groups | 2020 |
| Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).Diabetes Obes Metab | Random groups | 2020 |
| Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.J Clin Endocrinol Metab | Random groups | 2020 |
| Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.Diabetes Care | Random groups | 2019 |
| Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.Diabetes Care | Random groups | 2019 |
| Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.Lancet Diabetes Endocrinol | Random groups | 2019 |
| Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.Diabetes Obes Metab | Random groups | 2019 |
| Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.N Engl J Med | Random groups | 2019 |
| Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.Lancet | Random groups | 2019 |
| Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.Lancet Diabetes Endocrinol | Random groups | 2019 |
| Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.Lancet Diabetes Endocrinol | Random groups | 2019 |
| Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.Clin Pharmacokinet | Random groups | 2019 |
| Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.Lancet Diabetes Endocrinol | Random groups | 2019 |
| Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.JAMA | Random groups | 2019 |
| Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.Diabetes Obes Metab | Random groups | 2019 |
| Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.Sci Transl Med | Random groups | 2018 |
| Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial.Diabetes Obes Metab | Random groups | 2018 |
| A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.Diabetes Care | Random groups | 2018 |
| Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials.Diabetes Obes Metab | Random groups | 2018 |
| Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.Diabetes Obes Metab | Random groups | 2018 |
| Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.Lancet | Random groups | 2018 |
| A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.Expert Opin Drug Metab Toxicol | Random groups | 2018 |
| Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.Ann Pharmacother | Random groups | 2018 |
| Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.J Clin Endocrinol Metab | Random groups | 2018 |
| Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.Diabetes Obes Metab | Random groups | 2018 |
| A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.Adv Ther | Random groups | 2018 |
| Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.Lancet Diabetes Endocrinol | Random groups | 2018 |
| Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.Diabetes Obes Metab | Random groups | 2018 |
| Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.Diabetes Obes Metab | Random groups | 2018 |
| Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.Diabetes Care | Random groups | 2018 |
| Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.Diabetes Obes Metab | Random groups | 2018 |
| Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.JAMA | Random groups | 2017 |
| Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.Diabetes Obes Metab | Random groups | 2017 |
| Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.Diabetologia | Random groups | 2017 |
| Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.Lancet Diabetes Endocrinol | Random groups | 2017 |
| Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.Lancet Diabetes Endocrinol | Random groups | 2017 |
| Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.Lancet Diabetes Endocrinol | Random groups | 2017 |
| Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus.Am Fam Physician | Random groups | 2017 |
| Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.N Engl J Med | Random groups | 2016 |
| A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.Diabetes Care | Random groups | 2016 |
| Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.J Med Econ | No random groups | 2026 |
| Durability of Semaglutide Effects After Treatment Discontinuation in HIV-Associated Lipohypertrophy: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Clinical Trial.Open Forum Infect Dis | No random groups | 2026 |
| Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study.HIV Med | No random groups | 2026 |
| Semaglutide improves markers of cardiovascular risk in people with HIV.AIDS | No random groups | 2026 |
| Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8).Diabetes Obes Metab | No random groups | 2026 |
| Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.Diabetes Obes Metab | No random groups | 2026 |
| Effectiveness of Weekly Semaglutide Treatment (0.5 or 1 mg) in Chilean Patients with Type 2 Diabetes Mellitus.Rev Med Chil | No random groups | 2026 |
| Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study.Obes Surg | No random groups | 2026 |
| Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.J Clin Pharmacol | No random groups | 2026 |
| Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study.Cardiovasc Diabetol | No random groups | 2026 |
| Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity.Obesity (Silver Spring) | No random groups | 2026 |
| Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study.BMC Med | No random groups | 2026 |
| Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.J Med Econ | No random groups | 2025 |
| Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care.BMJ Open Diabetes Res Care | No random groups | 2025 |
| Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.Clin Infect Dis | No random groups | 2025 |
| PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.Adv Ther | No random groups | 2024 |
| 5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.Diabetes Obes Metab | No random groups | 2024 |
| Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.Obesity (Silver Spring) | No random groups | 2023 |
| Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.Diabetes Obes Metab | No random groups | 2022 |
| Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.J Diabetes Investig | No random groups | 2022 |
| Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.Diabetes Obes Metab | No random groups | 2022 |
| Cardiometabolic risk factors efficacy of semaglutide in the STEP program.Postgrad Med | No random groups | 2022 |
| Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.Cell Rep Med | No random groups | 2021 |
| Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial.Expert Opin Drug Metab Toxicol | No random groups | 2021 |
| Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.Clin Pharmacokinet | No random groups | 2021 |
| Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care.Am J Manag Care | No random groups | 2020 |
| Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.Clin Pharmacokinet | No random groups | 2019 |
| Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.Clin Pharmacokinet | No random groups | 2018 |
| Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.J Clin Pharmacol | No random groups | 2018 |
| Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.Diabetes Obes Metab | No random groups | 2018 |
| Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.Clin Pharmacokinet | No random groups | 2017 |
| Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.Clin Pharmacokinet | No random groups | 2017 |
| Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.J Obstet Gynaecol | Group followed over time | 2026 |
| Cup-To-Disc Ratio in Glucagon-Like Peptide 1 Receptor Agonist-Associated Nonarteritic Anterior Ischemic Optic Neuropathy.Ophthalmology | Group followed over time | 2026 |
| Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease.Medicine (Baltimore) | Group followed over time | 2026 |
| Applicability of Non-Invasive Eligibility Criteria for MASH Pharmacotherapy: A Multicentre Cohort Study.Liver Int | Group followed over time | 2026 |
| Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes.Diabetes Obes Metab | Group followed over time | 2026 |
| Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study.Ophthalmology | Group followed over time | 2026 |
| Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome.Front Endocrinol (Lausanne) | Group followed over time | 2026 |
| Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide.Diabetes Metab Res Rev | Group followed over time | 2026 |
| Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice.Endocrinol Diabetes Metab | Group followed over time | 2026 |
| Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes.Am J Kidney Dis | Group followed over time | 2026 |
| Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From the Chinese HARMONY Cohort.Diabetes Obes Metab | Group followed over time | 2026 |
| Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2).Minerva Endocrinol (Torino) | Group followed over time | 2026 |
| Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study.J Med Internet Res | Group followed over time | 2026 |
| Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study.Expert Rev Cardiovasc Ther | Group followed over time | 2026 |
| Implementation of the IWQOL-Lite-CT in Observational Research: Comparison of Baseline Scores With a Clinical Trial Population and Psychometric Evaluation.Clin Obes | Group followed over time | 2026 |
| GLP-1 receptor agonist therapy before bariatric surgery: Effects on weight loss and body composition in clinical practice.Obes Res Clin Pract | Group followed over time | 2026 |
| Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.Adv Ther | Group followed over time | 2026 |
| Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.Br J Ophthalmol | Group followed over time | 2026 |
| Real-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in patients with obesity: a prospective observational study.Sci Rep | Group followed over time | 2026 |
| Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital.J Assoc Physicians India | Group followed over time | 2026 |
| Combining GLP-1 Receptor Agonists and Health-Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real-World Single-Center Study.Pediatr Obes | Group followed over time | 2026 |
| Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system.J Manag Care Spec Pharm | Group followed over time | 2026 |
| Real-world impact of oral semaglutide on inflammatory markers in patients at high cardiovascular risk.Rev Clin Esp (Barc) | Group followed over time | 2026 |
| Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study.Diabetes Res Clin Pract | Group followed over time | 2026 |
| Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study.Aesthetic Plast Surg | Group followed over time | 2026 |
| SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.Diabetes Obes Metab | Group followed over time | 2026 |
| Adding Semaglutide to SGLT2 Inhibitors Reduces Liver Enzymes in Patients with Type 2 Diabetes Complicated by Metabolic Dysfunction Associated Steatotic Liver Disease: A Retrospective Observational Study.Intern Med | Group followed over time | 2026 |
| Effects of semaglutide, a GLP-1 receptor agonist, on food preferences in Japanese subjects with type 2 diabetes and visceral fat accumulation.Endocr J | Group followed over time | 2026 |
| BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.Curr Med Res Opin | Group followed over time | 2026 |
| Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.Diab Vasc Dis Res | Group followed over time | 2026 |
| Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study.Clin Nutr | Group followed over time | 2026 |
| GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.J Addict Med | Group followed over time | 2026 |
| Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice.Nutrients | Group followed over time | 2026 |
| Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.Metab Syndr Relat Disord | Group followed over time | 2026 |
| Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records.Clin Obes | Group followed over time | 2026 |
| Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes.Med Clin (Barc) | Group followed over time | 2026 |
| A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.Diabetes Obes Metab | Group followed over time | 2026 |
| Real-world glycemic control, exploratory cardiorenal indicators, and safety of polyethylene glycol loxenatide versus semaglutide in type 2 diabetes patients: a Chinese two-center retrospective cohort study.Front Endocrinol (Lausanne) | Group followed over time | 2026 |
| Impact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study.Endocrinol Diabetes Nutr (Engl Ed) | Group followed over time | 2026 |
| Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes.J Diabetes Investig | Group followed over time | 2026 |
| Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.Diabetes Obes Metab | Group followed over time | 2026 |
| Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).Diabetes Obes Metab | Group followed over time | 2026 |
| GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.J Pediatr Endocrinol Metab | Group followed over time | 2026 |
| Preliminary Real-World Experience with Semaglutide in Obese Patients with Type 2 Diabetes on Chronic Hemodialysis: A Multicenter Pilot Study.Medicina (Kaunas) | Group followed over time | 2026 |
| Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.ESC Heart Fail | Group followed over time | 2026 |
| Use of semaglutide after acute coronary syndrome: an exploratory retrospective study.J Cardiovasc Med (Hagerstown) | Group followed over time | 2026 |
| Predicting Weight Outcomes From Obesity Medications in a Paediatric Population.Pediatr Obes | Group followed over time | 2026 |
| Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.Expert Rev Pharmacoecon Outcomes Res | Group followed over time | 2026 |
| Patients after acute myocardial infarction: potential of semaglutide in prognosis for reducing events and mortality.Rev Clin Esp (Barc) | Group followed over time | 2026 |
| Real-world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network.Diabetes Obes Metab | Group followed over time | 2026 |
| One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population.Diabetes Obes Metab | Group followed over time | 2026 |
| The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population.Exp Clin Endocrinol Diabetes | Group followed over time | 2026 |
| Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder Risk and Psychological Distress in Adults With Class 3 Obesity.Int J Eat Disord | Group followed over time | 2026 |
| Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide.Ophthalmol Retina | Group followed over time | 2026 |
| Progression to type 2 diabetes among post-myocardial infarction patients with overweight or obesity: a real-world cohort study.Cardiovasc Diabetol | Group followed over time | 2026 |
| GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study.Br J Clin Pharmacol | Group followed over time | 2026 |
| Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors.Eur Heart J Qual Care Clin Outcomes | Group followed over time | 2025 |
| Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.Diabetes Obes Metab | Group followed over time | 2025 |
| Association of semaglutide use with outcomes in chronic plantar heel pain: a prospective observational cohort and a pilot interventional study.Int J Surg | Group followed over time | 2025 |
| Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD).J Med Econ | Group followed over time | 2025 |
| Potential protective role of GLP-1 receptor agonists for lithium-induced nephrotoxicity: a population-based observational study.CNS Spectr | Group followed over time | 2025 |
| Semaglutide and diabetic retinopathy: an OHDSI network study.BMJ Open Diabetes Res Care | Group followed over time | 2025 |
| Comparative effectiveness of OW GLP-1 RAs and other glucose-lowering therapies among Medicare beneficiaries with T2D and ASCVD.Diabetes Res Clin Pract | Group followed over time | 2025 |
| Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).Diabetes Obes Metab | Group followed over time | 2025 |
| Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.JAMA | Group followed over time | 2025 |
| Comparative effectiveness of GLP-1 RAs and other glucose-lowering therapies among Medicare Advantage beneficiaries with T2D and ASCVD.Curr Med Res Opin | Group followed over time | 2025 |
| Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study).Semin Arthritis Rheum | Group followed over time | 2025 |
| Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study.Adv Ther | Group followed over time | 2025 |
| Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts.Diabetes Obes Metab | Group followed over time | 2025 |
| Blinded by the drug? A vigilyze signal linking semaglutide to NAION.Int Ophthalmol | Group followed over time | 2025 |
| Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study.Front Endocrinol (Lausanne) | Group followed over time | 2025 |
| Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study.JMIR Form Res | Group followed over time | 2025 |
| Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.Diabetes Metab Syndr | Group followed over time | 2025 |
| PIONEER REAL Spain: A multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes.Diabetes Obes Metab | Group followed over time | 2025 |
| Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes.Med Clin (Barc) | Group followed over time | 2025 |
| Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.Am J Ophthalmol | Group followed over time | 2025 |
| Results of semaglutide in patients older than 70 years, a real-world study of efficacy and safety.Minerva Endocrinol (Torino) | Group followed over time | 2025 |
| Trends in glucagon-like peptide 1 receptor agonist prescribing patterns.Am J Manag Care | Group followed over time | 2025 |
| Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.JMIR Infodemiology | Group followed over time | 2025 |
| Clinical Effectiveness of Oral Semaglutide in Women with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Women_ENDO2S-RWD Substudy).Nutrients | Group followed over time | 2025 |
| Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease.Open Heart | Group followed over time | 2025 |
| Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study.Eur Heart J Cardiovasc Pharmacother | Group followed over time | 2025 |
| Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes.Sci Rep | Group followed over time | 2025 |
| Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies.Ann Intern Med | Group followed over time | 2025 |
| Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting.Acta Diabetol | Group followed over time | 2025 |
| Long-Term Effectiveness of Once-Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real-World Study.Diabetes Metab Res Rev | Group followed over time | 2025 |
| Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study.BMC Endocr Disord | Group followed over time | 2025 |
| Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.JAMA Ophthalmol | Group followed over time | 2025 |
| Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide.Medicina (Kaunas) | Group followed over time | 2025 |
| Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome.Int J Cardiol | Group followed over time | 2025 |
| Effects of semaglutide in patients with chronic ankle instability: evidence from a prospective cohort.J Orthop Surg Res | Group followed over time | 2025 |
| Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors Improve Renal Resistive Index in Patients With Type 2 Diabetes: A 26-Week Prospective Observational Real-Life Study.J Diabetes Res | Group followed over time | 2025 |
| Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.Adv Ther | Group followed over time | 2025 |
| Evaluation of gastric content in fasting patient during semaglutide use: an observational study.Surg Obes Relat Dis | Group followed over time | 2025 |
| Factors Associated With Semaglutide Initiation Among Adults With Obesity.JAMA Netw Open | Group followed over time | 2025 |
| Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.JAMA Psychiatry | Group followed over time | 2025 |
| Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.Dig Dis Sci | Group followed over time | 2024 |
| Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study.J Clin Anesth | Group followed over time | 2024 |
| REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.J Diabetes Complications | Group followed over time | 2024 |
| Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study.Anaesthesia | Group followed over time | 2024 |
| Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study.Diabetes Obes Metab | Group followed over time | 2024 |
| Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.Ann Saudi Med | Group followed over time | 2024 |
| Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data.J Diabetes Investig | Group followed over time | 2024 |
| Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.Diabetes Obes Metab | Group followed over time | 2024 |
| Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.Diabetes Obes Metab | Group followed over time | 2024 |
| Short-term effects of semaglutide among patients with obesity with and without food addiction: an observational study.J Addict Dis | Group followed over time | 2024 |
| Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation.Cardiovasc Diabetol | Group followed over time | 2024 |
| Semaglutide treatment for children with obesity: an observational study.Arch Dis Child | Group followed over time | 2024 |
| Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.JAMA Intern Med | Group followed over time | 2024 |
| Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study).Nutrients | Group followed over time | 2024 |
| Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study).BMC Endocr Disord | Group followed over time | 2024 |
| Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.Front Endocrinol (Lausanne) | Group followed over time | 2024 |
| Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia.Front Endocrinol (Lausanne) | Group followed over time | 2024 |
| Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).Endocr J | Group followed over time | 2024 |
| Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study.Medicine (Baltimore) | Group followed over time | 2024 |
| Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.Diabetes Obes Metab | Group followed over time | 2024 |
| Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study.Int J Obes (Lond) | Group followed over time | 2024 |
| The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study.Front Endocrinol (Lausanne) | Group followed over time | 2024 |
| Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).Clin Drug Investig | Group followed over time | 2024 |
| Weight loss associated with semaglutide treatment among people with HIV.AIDS | Group followed over time | 2024 |
| Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting.Endocrine | Group followed over time | 2024 |
| Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.J Diabetes Res | Group followed over time | 2024 |
| Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide.Pharmacol Res | Group followed over time | 2024 |
| Daily Glucose Profiles after Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus.Intern Med | Group followed over time | 2024 |
| Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.Front Endocrinol (Lausanne) | Group followed over time | 2023 |
| Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide.Can J Anaesth | Group followed over time | 2023 |
| Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.Prim Care Diabetes | Group followed over time | 2023 |
| Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.Diabetes Obes Metab | Group followed over time | 2023 |
| Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.Diabetes Obes Metab | Group followed over time | 2023 |
| Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.Diabetes Obes Metab | Group followed over time | 2023 |
| Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.Obes Surg | Group followed over time | 2023 |
| Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.Exp Clin Endocrinol Diabetes | Group followed over time | 2023 |
| Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.Adv Ther | Group followed over time | 2023 |
| Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).Front Endocrinol (Lausanne) | Group followed over time | 2022 |
| Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes.Acta Diabetol | Group followed over time | 2022 |
| Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.Front Endocrinol (Lausanne) | Group followed over time | 2022 |
| A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study.Adv Ther | Group followed over time | 2022 |
| Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.Front Endocrinol (Lausanne) | Group followed over time | 2022 |
| Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.Clin Ther | Group followed over time | 2022 |
| Weight Loss Outcomes With Telemedicine During COVID-19.Front Endocrinol (Lausanne) | Group followed over time | 2022 |
| Areas of Interest and Attitudes Toward Antiobesity Drugs: Thematic and Quantitative Analysis Using Twitter.J Med Internet Res | Group followed over time | 2021 |
| Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.Diabet Med | Group followed over time | 2021 |
| Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.Prim Care Diabetes | Group followed over time | 2021 |
| Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.Diabetes Obes Metab | Group followed over time | 2021 |
| Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.Diabetes Res Clin Pract | Group followed over time | 2021 |
| Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).Diabetes Obes Metab | Group followed over time | 2020 |
| Pigmented purpura dermatosis associated with compounded semaglutide: A case report and literature review of medication-associated pigmented purpuric dermatosis.JAAD Case Rep | Case reports | 2026 |
| BBS10-related Bardet-Biedl syndrome with an atypical presentation of diabetes mellitus: A case report.Exp Ther Med | Case reports | 2026 |
| Revision Medialization Thyroplasty for Glottic Insufficiency Amid Rapid Weight Loss on Semaglutide.Laryngoscope | Case reports | 2026 |
| Brain Neuromodulation via Endoscopic Gastric Implant Improves Glycemic Control in Insulin-Dependent Type-2 Diabetes: First-in-Human Feasibility and Autonomic Response Study.J Laparoendosc Adv Surg Tech A | Case reports | 2026 |
| Cutaneous vasculitis associated with subcutaneous semaglutide.Endocrinol Diabetes Nutr (Engl Ed) | Case reports | 2026 |
| SEMAGLUTIDE TREATMENT IN TWO VERY YOUNG CHILDREN WITH SEVERE EARLY-ONSET OBESITY.Horm Res Paediatr | Case reports | 2026 |
| GLP-1RA based treatment in patients with a PCSK1 mutation has profound effects on body weight - two case reports.Obes Facts | Case reports | 2026 |
| Weight Maintenance Following Discontinuation of Semaglutide in an Adolescent with Antipsychotic-Associated Weight Gain: A Case Report.Horm Res Paediatr | Case reports | 2026 |
| Severe Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report.Int Med Case Rep J | Case reports | 2026 |
| Starvation-associated high-anion gap metabolic acidosis following short-term oral semaglutide use: A case report.J Int Med Res | Case reports | 2026 |
| Cardiometabolic therapy for rhythm control: a case report of refractory atrial fibrillation resolving after initiation of semaglutide for obesity.Eur Heart J Case Rep | Case reports | 2026 |
| Novel cutaneous adverse effects of the increasingly prevalent glucagon-like peptide 1 agonists.Skin Health Dis | Case reports | 2026 |
| Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.JCEM Case Rep | Case reports | 2026 |
| Postmenopausal bleeding associated with semaglutide: a diagnostic challenge.JCEM Case Rep | Case reports | 2026 |
| Glucagon-like peptide-1 receptor agonists as adjunctive therapy in refractory hypertriglyceridemia following recurrent pancreatitis.JCEM Case Rep | Case reports | 2026 |
| Lithium Toxicity Following Initiation of Semaglutide in a Patient With Bipolar Disorder: A Case Report.Cureus | Case reports | 2026 |
| Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension.JACC Case Rep | Case reports | 2026 |
| Non-Arteritic Anterior Ischaemic Optic Neuropathy Associated with Semaglutide use.Ir Med J | Case reports | 2026 |
| Glucagon-Like Peptide-1 Agonist Effects on Weight Loss and Heart Failure Hemodynamics.JACC Case Rep | Case reports | 2026 |
| Case Report: Acute biliary pancreatitis after semaglutide dose escalation in an adolescent with obesity and cholelithiasis.Front Pediatr | Case reports | 2026 |
| Patulous Eustachian tube dysfunction following rapid weight loss associated with semaglutide use: A case report.SAGE Open Med Case Rep | Case reports | 2026 |
| Nonarteritic anterior ischemic optic neuropathy after rapid weight loss during semaglutide therapy: a case report.Korean J Fam Med | Case reports | 2026 |
| Acute pancreatitis following semaglutide therapy: a case report.Ann Med Surg (Lond) | Case reports | 2026 |
| Tirzepatide non-response with subsequent semaglutide response in class 2 obesity.JCEM Case Rep | Case reports | 2026 |
| Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.Case Rep Womens Health | Case reports | 2026 |
| Dramatic Improvement of Treatment-Refractory Prurigo Nodularis Following Initiation of Semaglutide: A Case Report.Clin Cosmet Investig Dermatol | Case reports | 2026 |
| Primary Colonic Mucosal-Associated Lymph Tissue Lymphoma: A Case Report.Case Rep Gastroenterol | Case reports | 2026 |
| Pharmacist-led medication therapy management improving medication adherence in a patient with type 2 diabetes: case report.Front Med (Lausanne) | Case reports | 2026 |
| Complex clinical encounter series: glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health?J Bone Miner Res | Case reports | 2026 |
| Hypoglycaemic coma induced by a falsified semaglutide product: a case report.Eur J Hosp Pharm | Case reports | 2026 |
| Prolonged Dysesthesia After Massive Accidental Semaglutide Overdose: A Case Report.J Am Coll Emerg Physicians Open | Case reports | 2026 |
| Glycaemic changes during early semaglutide treatment: a case of pancreatic adenocarcinoma.Acta Diabetol | Case reports | 2026 |
| Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes.Int J Clin Pharmacol Ther | Case reports | 2026 |
| 18 F-FDG PET/CT Five Days Post First Administration of Semaglutide : Side Effects in One Shot.Clin Nucl Med | Case reports | 2026 |
| Case Report: Oral semaglutide-associated depression in a patient with type 2 diabetes mellitus: a dose-dependent recurrence confirmed on rechallenge and managed with vortioxetine-bupropion combination therapy.Front Psychiatry | Case reports | 2026 |
| Semaglutide-Induced Sarcopenia via GLP-1R-mTOR-Satellite Cells Axis and Muscle-Glucose Feedback Loop Potentially Leading to Refractory Hyperglycemia in Type 2 Diabetes: A Case-Driven Hypothesis.Probl Endokrinol (Mosk) | Case reports | 2026 |
| Severe Gastrointestinal Intolerance After Resuming Maintenance-Dose Semaglutide Following Ramadan-Related Treatment Interruption: A Case Report.Cureus | Case reports | 2026 |
| Semaglutide for Refractory Reactive Hypoglycaemia: A Case Report.Cureus | Case reports | 2026 |
| Where did the iron go?-a case report of a patient with severe iron deficiency anemia despite parenteral and oral iron supplementation due to semaglutide application.AME Case Rep | Case reports | 2026 |
| Severe Perioperative Lactic Acidosis and Hyperglycemia Responsive to Thiamine in a Patient With Prior Semaglutide Use and Restrictive Dieting: A Case Report.A A Pract | Case reports | 2026 |
| Déjà vu! A Case of Recurrent Metabolic Dysfunction-Associated Steatohepatitis 70 Days After Liver Transplantation.ACG Case Rep J | Case reports | 2026 |
| Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.BMC Ophthalmol | Case reports | 2026 |
| Concurrent diabetic ketoacidosis, acute pancreatitis, and subsequent ruptured acalculous cholecystitis in a patient receiving semaglutide: A case report.SAGE Open Med Case Rep | Case reports | 2026 |
| Atypical retrobulbar optic neuropathy after semaglutide escalation.JCEM Case Rep | Case reports | 2026 |
| "Ozempic Limb": Understanding the Impact of Semaglutide on Prosthesis Use and Residual Limb Care in Individuals With Lower Limb Amputation.Am J Phys Med Rehabil | Case reports | 2026 |
| Simultaneous bilateral NAION following initiation of high-dose semaglutide: a case report.Arch Soc Esp Oftalmol (Engl Ed) | Case reports | 2026 |
| Too much of a good thing.Surv Ophthalmol | Case reports | 2026 |
| Case Report: Latent autoimmune diabetes in two young female patients successfully treated with oral semaglutide and basal insulin.Front Endocrinol (Lausanne) | Case reports | 2026 |
| [Insulin intoxications caused by falsified semaglutide].Ned Tijdschr Geneeskd | Case reports | 2026 |
| Adult Annular Pancreas Presenting With Gastric Outlet Obstruction Following Semaglutide Initiation: A Case Report.Cureus | Case reports | 2026 |
| Acute Nutritional Axonal Neuropathy in the Setting of Semaglutide-Associated Gastrointestinal Intolerance: A Case Report.Case Rep Neurol | Case reports | 2026 |
| Can semaglutide influence tumor biomarkers? Insight from a clinical case.J Food Drug Anal | Case reports | 2026 |
| Boerhaave's syndrome associated with glucagon-like peptide-1 receptor agonist use: a case report.J Cardiothorac Surg | Case reports | 2026 |
| Photodistributed exfoliative dermatitis associated with semaglutide: Expanding the spectrum of glucagon-like peptide-1 receptor agonist-associated cutaneous reactions.JAAD Case Rep | Case reports | 2026 |
| Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment.JCEM Case Rep | Case reports | 2026 |
| Semaglutide-associated Twiddler syndrome.JCEM Case Rep | Case reports | 2026 |
| Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes.Pediatrics | Case reports | 2026 |
| Remission of erythromelalgia after semaglutide initiation: A case report.JAAD Case Rep | Case reports | 2026 |
| Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction.J Diabetes Investig | Case reports | 2026 |
| Asymptomatic Subcutaneous Semaglutide Overdose: A Case Report and Literature Review.J Pharm Pract | Case reports | 2026 |
| Type B insulin resistance with glycemic extremes: a case report and literature review.Front Endocrinol (Lausanne) | Case reports | 2026 |
| Metabolic and nutritional stress-associated dilated cardiomyopathy in the setting of semaglutide use and long-term nicotine replacement therapy: a case report and literature review.Ther Adv Drug Saf | Case reports | 2026 |
| Angioedema After Accidental Semaglutide Dosing Error: A Case Report.J Clin Med | Case reports | 2026 |
| Quadruple Non-Insulin Therapy for Advanced Type 2 Diabetes Mellitus With Cognitive Impairment: A Case Report.Cureus | Case reports | 2026 |
| Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge.JCEM Case Rep | Case reports | 2026 |
| Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gaps.J Am Pharm Assoc (2003) | Case reports | 2026 |
| Mixed Medullary and Papillary Thyroid Carcinoma in a Patient on Tirzepatide.Cureus | Case reports | 2026 |
| Euthyroid Sick Syndrome Precipitated By Rapid Weight Loss Following Semaglutide Initiation: A Case Report.Clin Med Insights Endocrinol Diabetes | Case reports | 2026 |
| Glucagon-Like Peptide-1 Receptor Agonists in the Management of Mitochondrial Diabetes in an Adolescent: A Case Report.Horm Res Paediatr | Case reports | 2026 |
| Familial partial lipodystrophy type 2 associated with a novel LMNA variant (c.604G>C; p.Glu202Gln): a Colombian family case series.Front Endocrinol (Lausanne) | Case reports | 2026 |
| Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis.ACG Case Rep J | Case reports | 2026 |
| Spontaneous Pneumomediastinum Associated with Semaglutide Therapy: A Case Report.Case Rep Gastroenterol | Case reports | 2026 |
| Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults.Sr Care Pharm | Case reports | 2026 |
| Semaglutide as a potential tool in pre-lung transplant weight loss optimization.JCEM Case Rep | Case reports | 2026 |
| A case of type 2 diabetes with spinal and bulbar muscular atrophy treated with oral semaglutide while sparing muscle reduction for two years: a case report with literature review.Diabetol Int | Case reports | 2026 |
| Semaglutide exposure in early pregnancy and pregnancy outcomes: A case report and review of literature.J Gynecol Obstet Hum Reprod | Case reports | 2026 |
| Resolution of central sleep apnea following upper airway surgery: A case report.Sleep Med | Case reports | 2026 |
| Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab.Intern Med | Case reports | 2026 |
| Semaglutide-Associated Acute Pancreatitis in a Patient With Type 2 Diabetes Mellitus: A Case Report.Cureus | Case reports | 2026 |
| Altered Mental Status Due to Amantadine Withdrawal: A Case Report.Reports (MDPI) | Case reports | 2026 |
| Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor?BMJ Case Rep | Case reports | 2026 |
| Tirzepatide-Induced Liver Injury: A Rare Complication.AACE Endocrinol Diabetes | Case reports | 2026 |
| A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young.AACE Endocrinol Diabetes | Case reports | 2026 |
| Nutritional Vulnerability in RYGB Unmasked by GLP-1 Therapy.ACG Case Rep J | Case reports | 2026 |
| [Semaglutide-induced acute-on-chronic liver failure: A case report and literature review].Zhong Nan Da Xue Xue Bao Yi Xue Ban | Case reports | 2026 |
| Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm.Reports (MDPI) | Case reports | 2026 |
| A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis.Cureus | Case reports | 2026 |
| [Onset of type 1 diabetes after treatment with online-prescribed semaglutide].Ugeskr Laeger | Case reports | 2026 |
| Unexpected Residual Gastric Contents in a Patient After Holding Semaglutide After Standard Fasting Guidelines: A Case Report.A A Pract | Case reports | 2026 |
| Complete radiologic and clinical reversal of lumbar spinal epidural lipomatosis via GLP-1 agonist.J Surg Case Rep | Case reports | 2026 |
| Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.Ment Health Clin | Case reports | 2026 |
| Efficacy of semaglutide in IgA nephropathy with obesity: a case report.BMC Nephrol | Case reports | 2026 |
| Liver benefits of early initiation of low-dose GLP-1 receptor agonists in newly diagnosed type 2 diabetes - A case report.J Family Med Prim Care | Case reports | 2026 |
| Pleural and Pericardial Effusions Associated with Semaglutide: A Case Report.Clin Pract Cases Emerg Med | Case reports | 2026 |
| Treatment Approaches for Obesity in Children With Heterozygous MC4R Variants.Clin Obes | Case reports | 2026 |
| Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss.Cureus | Case reports | 2026 |
| Pancreatic Mucinous Cystic Neoplasms Following GLP-1 Receptor Agonists Use: A Report of Two Cases with Literature Review.J Gastrointest Cancer | Case reports | 2026 |
| Investigating the Link Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Non-arteritic Ischemic Optic Neuropathy: A Case Report of Semaglutide-Induced Optic Neuropathy.Cureus | Case reports | 2026 |
| Recurrent bilateral brachial plexus neuritis following rapid semaglutide-induced weight loss: a case report.BMC Neurol | Case reports | 2026 |
| Unmasking an insulinoma: recurrent Hypoglycemia in a young patient following GLP-1 receptor agonist therapy -A case report.Oxf Med Case Reports | Case reports | 2026 |
| Non-Arteritic Ischaemic Optic Neuropathy Associated with Semaglutide Use.Ir Med J | Case reports | 2026 |
| Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report.Cureus | Case reports | 2026 |
| Ischemic Colitis Associated With Tirzepatide Therapy in a Young Female Patient: A Case Report.Cureus | Case reports | 2026 |
| Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report.Cureus | Case reports | 2026 |
| Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report.Cureus | Case reports | 2026 |
| The Role of Glucagon-Like Peptide-1 Receptor Agonists in Prompting a Meaningful Improvement in Alcohol Use Disorder.J Prim Care Community Health | Case reports | 2026 |
| GLP-1 receptor agonist-associated eosinophilic duodenitis presenting as a bowel obstruction : a case report and literature review.Acta Gastroenterol Belg | Case reports | 2026 |
| Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women.AACE Endocrinol Diabetes | Case reports | 2026 |
| GLP-1 Receptor Agonist-Associated Slimmer's Palsy: Implications for the Peripheral Nerve Surgeon.Ann Plast Surg | Case reports | 2026 |
| Case Series of Nizon-Isidor Syndrome by Heterozygous Variants in MED12L With Further Evidence of Mitotic Instability in One Case With Diploid-Triploid Mosaicism.Am J Med Genet A | Case reports | 2026 |
| Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report.Lung Cancer (Auckl) | Case reports | 2025 |
| Unanticipated Residual Gastric Contents in an Appropriately Fasted Pediatric Patient on Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Case Report and Review of Perioperative Considerations.Cureus | Case reports | 2025 |
| A Case Report of Bezoar-Induced Small Bowel Obstruction: A Potential Surgical Complication of Semaglutide.Cureus | Case reports | 2025 |
| Mirtazapine for gastrointestinal side effects of glucagon-like peptide-1 receptor agonist therapy in older adults.Endocr Regul | Case reports | 2025 |
| Blurring Fact and Fiction: A Complex Case of Recurrent Emergency Presentations, Polypharmacy, and Psychiatric Conflict.Cureus | Case reports | 2025 |
| Short-Term Semaglutide Improves Safety in High Body Weight Recipients Undergoing Living Donor Liver Transplant: A Case Report.Exp Clin Transplant | Case reports | 2025 |
| From weight loss to muscle loss: rhabdomyolysis linked to semaglutide.Clin Kidney J | Case reports | 2025 |
| Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome.JCEM Case Rep | Case reports | 2025 |
| Optic disc edema during semaglutide therapy: case report and literature review.Am J Ophthalmol Case Rep | Case reports | 2025 |
| Coincidence of Autoimmune Diabetes Mellitus and Familial Partial Lipodystrophy.JCEM Case Rep | Case reports | 2025 |
| Worsening vasomotor symptoms in the setting of estradiol and semaglutide: a case report.Menopause | Case reports | 2025 |
| First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss.Eur Arch Otorhinolaryngol | Case reports | 2025 |
| Use of obesity medications in a young pediatric patient with optic nerve hypoplasia and severe early-onset obesity: A case report.Obes Pillars | Case reports | 2025 |
| Neurological complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use: a case report.BMC Neurol | Case reports | 2025 |
| Inflammatory optic neuritis and scleritis following commencement of semaglutide: a case report.J Surg Case Rep | Case reports | 2025 |
| Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome.J Clin Endocrinol Metab | Case reports | 2025 |
| A Case of Slowly Progressive Type 1 Diabetes Mellitus (SPIDDM, Probable) Successfully Managed With Oral Semaglutide for Glycemic Control and Weight Management Accompanied by Changes in Eating Behavior.Cureus | Case reports | 2025 |
| Comparison of Fracture Risk Following Semaglutide Treatment vs Sleeve Gastrectomy.AACE Endocrinol Diabetes | Case reports | 2025 |
| Semaglutide-associated psychiatric disorders: A case report and literature review.Endocrinol Diabetes Nutr (Engl Ed) | Case reports | 2025 |
| Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.J Clin Psychopharmacol | Case reports | 2025 |
| Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.Eur J Clin Nutr | Case reports | 2025 |
| Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report.Cancer Chemother Pharmacol | Case reports | 2025 |
| Bariatric surgery and semaglutide in a youth with juvenile Huntington disease and severe obesity: a case report.J Med Case Rep | Case reports | 2025 |
| Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.SAGE Open Med Case Rep | Case reports | 2025 |
| Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.Cureus | Case reports | 2025 |
| Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report.Front Endocrinol (Lausanne) | Case reports | 2025 |
| Semaglutide-associated drug-induced liver injury: a case report and review of the literature.Oxf Med Case Reports | Case reports | 2025 |
| Semaglutide in the treatment of a patient with type 2 diabetes mellitus, psoriasis, and metabolic dysfunction-associated steatotic liver disease: a case report.Front Med (Lausanne) | Case reports | 2025 |
| A Novel Presentation of Euglycemic Diabetic Ketoacidosis Associated with SGLT2 Inhibitor and Weekly GLP-1 Agonist: Case Report.Healthcare (Basel) | Case reports | 2025 |
| Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient.Cureus | Case reports | 2025 |
| Increased Weight Loss With the Combination of Levoketoconazole and Semaglutide in a Patient With Mild Hypercortisolism.AACE Endocrinol Diabetes | Case reports | 2025 |
| Alopecia areata following semaglutide treatment for weight loss: A case report.JAAD Case Rep | Case reports | 2025 |
| Type 2 Diabetes in a 4-Year-Old With Obesity: Considerations for Use of Semaglutide and Bariatric Surgery in Children.JCEM Case Rep | Case reports | 2025 |
| New onset diabetic retinopathy with glucagon-like peptide-1 receptor agonists: A case report.J Am Pharm Assoc (2003) | Case reports | 2025 |
| Herpes Zoster Occurring After Injection of Botulinum Toxin and Hyaluronic Acid.J Craniofac Surg | Case reports | 2025 |
| Semaglutide as a potential therapeutic adjunct for reducing flare-ups in Sjögren's syndrome: A case report.SAGE Open Med Case Rep | Case reports | 2025 |
| Case Report: Clinical pharmacist prescriber in depression treatment in primary care settings: clinical case focused on prescribing practice.Front Psychiatry | Case reports | 2025 |
| Subjective Olfactory Impairment in a Patient Undergoing Anti-Obesity Pharmacotherapy: A Case of Symptom-Test Discrepancy.Life (Basel) | Case reports | 2025 |
| Food noise: A theoretical review.Appetite | Review of studies | 2027 |
| The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.J Diabetes Metab Disord | Review of studies | 2026 |
| GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific risk.N Am Spine Soc J | Review of studies | 2026 |
| Protecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy.Child Obes | Review of studies | 2026 |
| GLP-1 receptor agonists in adolescent obesity: Incretin-based therapies during a sensitive developmental period.Appetite | Review of studies | 2026 |
| GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.Ann Med | Review of studies | 2026 |
| Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy.J Endocr Soc | Review of studies | 2026 |
| Weight gain, adipose tissue remodeling and cardiometabolic disease in people with HIV.Curr Opin HIV AIDS | Review of studies | 2026 |
| Semaglutide in postmenopausal women: Clinical implications for weight loss, muscle health, and sleep-disordered breathing.Maturitas | Review of studies | 2026 |
| GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension.Exp Gerontol | Review of studies | 2026 |
| Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications.Curr Opin Nephrol Hypertens | Review of studies | 2026 |
| Analytical methods for the determination of semaglutide in pharmaceutical formulations and biological matrices: A comprehensive review.J Chromatogr B Analyt Technol Biomed Life Sci | Review of studies | 2026 |
| From adiposity to multisystem morbidity: the case for weight loss as disease modification.Lancet Diabetes Endocrinol | Review of studies | 2026 |
| Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.Aliment Pharmacol Ther | Review of studies | 2026 |
| From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic framework.Curr Probl Cardiol | Review of studies | 2026 |
| Advances in Cardiovascular Pharmacotherapy. IX. Protection Against Major Adverse Cardiovascular Events by Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Obesity.J Cardiothorac Vasc Anesth | Review of studies | 2026 |
| Perioperative management of GLP-1 receptor agonists: a structured narrative review with considerations relevant to neurosurgical patients.J Endocrinol Invest | Review of studies | 2026 |
| Advances in proteomics research related to semaglutide: evidence from humans and animals.J Endocrinol Invest | Review of studies | 2026 |
| Semaglutide in Heart Failure With Preserved Ejection Fraction: Exploring Recent Evidence in Therapeutic Potential for the Obese Population.Cardiol Rev | Review of studies | 2026 |
| The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration.Metabolism | Review of studies | 2026 |
| Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.Drugs | Review of studies | 2026 |
| Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses.Expert Opin Pharmacother | Review of studies | 2026 |
| GLP-1-Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection.Diabetes Obes Metab | Review of studies | 2026 |
| Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity.Rambam Maimonides Med J | Review of studies | 2026 |
| The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome.Diabetes Metab Syndr Obes | Review of studies | 2026 |
| Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review.Arch Osteoporos | Review of studies | 2026 |
| Gut-brain axis in Alzheimer's disease: neuroinflammatory mechanisms and immunopharmacological interventions.Inflammopharmacology | Review of studies | 2026 |
| GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications.Eur J Clin Pharmacol | Review of studies | 2026 |
| Pharmacotherapy for MASLD: current evidence and challenges in clinical practice.Ann Hepatol | Review of studies | 2026 |
| How Well Are We Measuring Nausea? A Narrative Review of Patient-Reported Outcome Gaps in GLP-1 Receptor Agonist Obesity Trials.Diabetes Obes Metab | Review of studies | 2026 |
| Emerging Therapeutic Strategies for Child and Adolescent Obesity: A Narrative Review.Nutrients | Review of studies | 2026 |
| Chronic Intermittent Hypoxia and MASLD in Obstructive Sleep Apnea: A Critical Appraisal of Mechanistic and Causal Evidence.Int J Mol Sci | Review of studies | 2026 |
| Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies.Curr Obes Rep | Review of studies | 2026 |
| Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review.Front Endocrinol (Lausanne) | Review of studies | 2026 |
| Obesity: oral therapy for those afraid of needles.Expert Opin Pharmacother | Review of studies | 2026 |
| Advances in disease management and treatment outcomes for obesity and knee osteoarthritis in primary care practice.Curr Med Res Opin | Review of studies | 2026 |
| Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder: A Narrative Review of Available Clinical Evidence.Biol Psychiatry | Review of studies | 2026 |
| Glucagon-Like Peptide-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From Rats to Humans.Biol Psychiatry | Review of studies | 2026 |
| GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies.Biol Psychiatry | Review of studies | 2026 |
| Do Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.Aesthet Surg J | Review of studies | 2026 |
| Glucagon-Like Peptide-1 Receptor Agonists for Mood Disorders and Suicide Risk.Biol Psychiatry | Review of studies | 2026 |
| Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation.Biol Psychiatry | Review of studies | 2026 |
| Emerging therapies for knee osteoarthritis.Nat Rev Rheumatol | Review of studies | 2026 |
| GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?Acta Diabetol | Review of studies | 2026 |
| Effects of glucagon-like peptide-1 (GLP-1) mono-agonists on reward processing in animal models: a systematic review.Acta Neuropsychiatr | Review of studies | 2026 |
| Pharmacotherapy for MASLD/MASH: approved therapies, drug repurposing, and emerging mechanism-based candidates.Expert Opin Pharmacother | Review of studies | 2026 |
| The therapeutic potential of GLP-1 receptor agonists in central nervous system diseases: immune cell modulation and neuroinflammation.Expert Rev Clin Immunol | Review of studies | 2026 |
| Energy-Based Devices for GLP-1 Receptor Agonist-Associated Facial Aging: A Tissue-Specific Safety Framework.Clin Cosmet Investig Dermatol | Review of studies | 2026 |
| Adherence and Persistence to Injectable versus Oral GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Comparative Systematic Review and Analysis.Diabetes Metab Syndr Obes | Review of studies | 2026 |
| Semaglutide, Other GLP-1 Receptor Agonists, and Papillary Thyroid Carcinoma: A Narrative Review of Risk, Progression, and Mechanisms.J Clin Med | Review of studies | 2026 |
| The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.Obes Rev | Review of studies | 2026 |
| Cardiometabolic Substrate Modification in Atrial Fibrillation: Obesity and Epicardial Adipose Tissue in the Era of Incretin-Based Therapies and Catheter Ablation.J Cardiovasc Dev Dis | Review of studies | 2026 |
| Exploring semaglutide for alcohol use disorder: A review of clinical efficacy and neurobiological mechanisms.Addict Behav | Review of studies | 2026 |
| Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective.Pharmaceutics | Review of studies | 2026 |
| Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review.Metabolites | Review of studies | 2026 |
| Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review.Med Sci (Basel) | Review of studies | 2026 |
| Oral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification.Drug Des Devel Ther | Review of studies | 2026 |
| Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review.BMJ Med | Review of studies | 2026 |
| GDF-15/GFRAL Axis Dynamics and Vulnerability Windows in Bariatric Surgery: Pathophysiological, Microbiomic, and Pharmacological Perspectives.Cells | Review of studies | 2026 |
| Endocrine determinants of MASLD: mechanisms and therapeutic targets.Front Endocrinol (Lausanne) | Review of studies | 2026 |
| Potential Physiological Convergence Between GLP-1 Receptor Signaling and Hepatocyte TAZ in Metabolic Liver Disease: From Metabolic Homeostasis to Fibrotic Remodeling.Cells | Review of studies | 2026 |
| Comorbid Cardiovascular-Liver Disease Disparities: Current Understanding and Future Directions.Curr Cardiol Rep | Review of studies | 2026 |
| Perioperative management of patients taking GLP-1 receptor agonists: A comparative review of international clinical guidelines.Saudi J Anaesth | Review of studies | 2026 |
| Single or multiple nutritional hormone receptor modulators for chronic kidney disease.Clin Kidney J | Review of studies | 2026 |
| Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutr Clin Pract | Review of studies | 2026 |
| Effect of GLP-1 receptor agonist on nutrient intake: A narrative review.Nutr Clin Pract | Review of studies | 2026 |
| Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review.Neth Heart J | Review of studies | 2026 |
| A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy.Obes Sci Pract | Review of studies | 2026 |
| Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Ann Intern Med | Review of studies | 2026 |
| Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society.Maturitas | Review of studies | 2026 |
| From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists.Transl Res | Review of studies | 2026 |
| Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.Adv Ther | Review of studies | 2026 |
| The neuroendocrine-appetite-mental health triangle in PMOS: Implications for GLP-1 receptor agonist therapy.Neurosci Biobehav Rev | Review of studies | 2026 |
| GLP-1 receptor agonists in pediatric obesity.Dig Liver Dis | Review of studies | 2026 |
| Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective.Surg Obes Relat Dis | Review of studies | 2026 |
| Selecting Pharmacologic Interventions for MASH.Dig Dis Sci | Review of studies | 2026 |
| Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities.Int J Eat Disord | Review of studies | 2026 |
| Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.Ann Otol Rhinol Laryngol | Review of studies | 2026 |
| What obgyns need to know about GLP-1 receptor agonists.Curr Opin Obstet Gynecol | Review of studies | 2026 |
| Cutaneous Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Cureus | Review of studies | 2026 |
| GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review.Int J Mol Sci | Review of studies | 2026 |
| GLP-1-Based therapies for obesity-related heart failure with preserved ejection fraction: an umbrella review incorporating broader heart failure and cardiometabolic evidence.Front Cardiovasc Med | Review of studies | 2026 |
| Glucagon-like Peptide-1-based and Emerging Cardiometabolic Therapies in Heart Failure with Preserved Ejection Fraction: Linking Molecular Mechanisms to Clinical Outcomes.Card Fail Rev | Review of studies | 2026 |
| Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.Intern Med J | Review of studies | 2026 |
| Semaglutide in Atrial Arrhythmias: State of the Art and Future Perspectives.J Pers Med | Review of studies | 2026 |
| Cardiovascular outcomes of oral incretin-based drugs in type 2 diabetes: a GRADE-assessed meta-analysis of 67,679 patients.Front Cardiovasc Med | Review of studies | 2026 |
| EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy.J Hepatol | Review of studies | 2026 |
| Metabolic effects of a GLP-1 analog combined with aerobic training in ovariectomized rats.Mol Cell Endocrinol | In animals | 2027 |
| Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/δ-opioid receptor pathway.Neuropharmacology | In animals | 2026 |
| Reprogramming NAD+ homeostasis and FOXO3a-Nrf2 signaling mitigates bleomycin-driven pulmonary fibrosis.Toxicol Appl Pharmacol | In animals | 2026 |
| Beyond weight loss: Disentangling the direct effects of semaglutide vs equivalent calorie restriction on reproductive systems of male and female rats.Mol Metab | In animals | 2026 |
| Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.Physiol Behav | In animals | 2026 |
| Lipid-lowering and hepatoprotective effects of Ocimum sanctum L. (Thai holy basil) flower against MASLD and liver inflammation in rats.Food Res Int | In animals | 2026 |
| Semaglutide/Acarbose combination protects against diabetic nephropathy in rats; a novel insight into modulation of Nrf-2/HO-1& TGF-β/Smad pathways.Int Immunopharmacol | In animals | 2026 |
| An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.Proc Natl Acad Sci U S A | In animals | 2026 |
| Semaglutide and Tirzepatide Suppress Hepatic Fatty Acid Uptake and Fatty Acid β-Oxidation in High-Fat Diet-Induced Obesity Mice.J Proteome Res | In animals | 2026 |
| Effects of Blueberry and Collard Greens Dietary Intervention on Metabolic and Inflammatory Biomarkers in Zucker Obese Rats.Nutrients | In animals | 2026 |
| Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.Nat Metab | In animals | 2026 |
| A noninvasive 13C-mannitol breath test to monitor semaglutide treatment-induced delayed oral-cecal transit in mice.Am J Physiol Endocrinol Metab | In animals | 2026 |
| Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.Int J Obes (Lond) | In animals | 2026 |
| Incretin-based therapies and altered myocardial metabolism in a swine model of ischemic heart disease in the setting of metabolic syndrome.Surgery | In animals | 2026 |
| Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats.Behav Pharmacol | In animals | 2026 |
| Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome.Med Sci (Basel) | In animals | 2026 |
| Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model.PLoS One | In animals | 2026 |
| Combination GLP-1RA and Low-Dose IL-2 Modulates Peripheral Immune Activation and Attenuates CNS Inflammatory Transcript Signatures In Vivo.Int J Mol Sci | In animals | 2026 |
| Late-life semaglutide treatment slows ageing and extends lifespan in female mice.Nature | In animals | 2026 |
| PYY3-36 potentiates semaglutide-mediated mitochondrial modulation in MASLD.Am J Physiol Endocrinol Metab | In animals | 2026 |
| A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.Diabetes Obes Metab | In animals | 2026 |
| Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice.Diabetes | In animals | 2026 |
| Semaglutide exerts anti-pulmonary fibrosis effects by inhibiting cellular senescence through activation of the Sirt1/HSF1/HSPs pathway.Biochem Pharmacol | In animals | 2026 |
| Electrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery: A Promising Alternative to Conventional Semaglutide Formulations.Diabetes Obes Metab | In animals | 2026 |
| Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease.Bone | In animals | 2026 |
| Leucine supplementation modulates body composition and early weight rebound during GLP-1 receptor agonist therapy in diet-induced obese mice.J Endocrinol Invest | In animals | 2026 |
| Electroacupuncture enables semaglutide dose sparing in type 2 diabetes by boosting drug concentration and suppressing β-cell apoptosis.Front Endocrinol (Lausanne) | In animals | 2026 |
| Semaglutide Alleviates LPS-Induced Cognitive Disorder via O-GlcNAcylation of AKT-mTOR Signaling Pathway Components.Neuromolecular Med | In animals | 2026 |
| AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice.Proc Natl Acad Sci U S A | In animals | 2026 |
| GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis.Stem Cell Reports | In animals | 2026 |
| Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters.JCI Insight | In animals | 2026 |
| Can Carica papaya Serve as an Adjunct to Semaglutide in Mitigating Diabetes-Induced Testicular Injury Through Modulation of Oxidative Stress, Inflammation, Apoptosis, and the miR-34c/miR-155-SIRT1/FOXO1 Axis? An Experimental and Chem-Bio-Informatics Study.Int J Mol Sci | In animals | 2026 |
| A Novel Microfluidic Strategy for the Fabrication of α-Lactalbumin Nanomicelles Paves a New Path for Antiobesity Technology.Adv Healthc Mater | In animals | 2026 |
| Chronic semaglutide alters ingestive behavior without impairing taste function in mice.Mol Metab | In animals | 2026 |
| Semaglutide treatment reverses HFD induced hippocampal microglia activation and improves cognitive dysfunction.Tissue Cell | In animals | 2026 |
| Transforming a protease inhibitor into a peptide Guardian: BBI-armed hydrogel beads for Oral delivery of active peptides.Food Res Int | In animals | 2026 |
| AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models.Nat Commun | In animals | 2026 |
| Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease.Cell Rep Med | In animals | 2026 |
| Negative effects of semaglutide on bone in obese mice.Cell Rep Med | In animals | 2026 |
| The Crunchometer, a low-cost, open-source acoustic analysis of feeding microstructure.Elife | In animals | 2026 |
| Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice.Mol Brain | In animals | 2026 |
| The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.Cell Metab | In animals | 2026 |
| Enhanced Stability and Transdermal Delivery of Semaglutide Using an L-Arginine Based Dissolving Microneedle System.AAPS PharmSciTech | In animals | 2026 |
| Thermosensitive hydrogels for sustained semaglutide release: overcoming weight loss plateau in diet-induced obese rats.Pharm Dev Technol | In animals | 2026 |
| GLP-1 Receptors Are Enriched in the Lymphatic Endothelium and Their Pharmacological Activation With Semaglutide Improves the Pumping Capacity of Lymphatic Vessels.Microcirculation | In animals | 2026 |
| Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.Am J Physiol Renal Physiol | In animals | 2026 |
| Semaglutide ameliorates neuroinflammation and cognitive impairment in APP/PS1 mice.Mol Cell Biochem | In animals | 2026 |
| OGT Ameliorates Diabetes-Associated Cognitive Decline via Modulation of DRP1 Function and Mitochondrial Homeostasis.Diabetes Obes Metab | In animals | 2026 |
| Semaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study.Front Biosci (Landmark Ed) | In animals | 2026 |
| Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice.Int J Mol Sci | In animals | 2026 |
| 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss.Proc Natl Acad Sci U S A | In animals | 2026 |
| Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis.BMC Gastroenterol | In animals | 2026 |
| Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons.Nat Metab | In animals | 2026 |
| Combination therapy with clinically approved PPARα/δ/γ subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model.Biomed Pharmacother | In animals | 2026 |
| Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats.Neuropsychopharmacology | In animals | 2026 |
| Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model.Am J Physiol Gastrointest Liver Physiol | In animals | 2026 |
| Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss.Diabetes | In animals | 2026 |
| Semaglutide Inhibits Neuronal Apoptosis and Improves Cognitive Function in Mice after Traumatic Brain Injury, Mainly via the Caspase-Dependent Pathway.Neurocrit Care | In animals | 2026 |
| Semaglutide Inhibits Osteoblast Ferroptosis Induced by Diabetic Periodontitis via Modulating the Wnt5a/Ror2/p38 MAPK Signaling Pathway.Drug Des Devel Ther | In animals | 2026 |
| Insulin and Incretin Receptor Agonists Reciprocally Alter Their Blood-Brain Barrier Permeabilities.Int J Mol Sci | In animals | 2026 |
| On indirect negative inotropic effects of muscarine in the isolated human atrium.Naunyn Schmiedebergs Arch Pharmacol | In a lab dish | 2026 |
| Sirtuin 1 deficiency mediates chronic kidney disease-induced inflammaging cardiovascular calcification.Mol Biomed | In a lab dish | 2026 |
| Semaglutide Ameliorates Hepatocyte Steatosis in a Cell Co-Culture System by Downregulating the IRE1α-XBP1-C/EBPα Signaling Pathway in Macrophages.Pharmacology | In a lab dish | 2025 |
| Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system.Nat Commun | In a lab dish | 2024 |
| In vitro cell cultures of Brunner's glands from male mouse to study GLP-1 receptor function.Am J Physiol Cell Physiol | In a lab dish | 2022 |
| Pharmacy students' knowledge and attitudes regarding GLP-1 receptor agonist adverse effects in obesity management: a cross-sectional study.Libyan J Med | Other paper | 2026 |
| Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.Int J Qual Stud Health Well-being | Other paper | 2026 |
| ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations.Spectrochim Acta A Mol Biomol Spectrosc | Other paper | 2026 |
| Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran.J Diabetes Metab Disord | Other paper | 2026 |
| Evaluating the safety of glucagon-like peptide-1 agonist use in non-diabetic overweight patients undergoing shoulder arthroplasty.J Shoulder Elb Arthroplast | Other paper | 2026 |
| Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort.Clin Obes | Other paper | 2026 |
| Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.J Diabetes Metab Disord | Other paper | 2026 |
| Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic program.Am J Prev Cardiol | Other paper | 2026 |
| Delays in access to generic semaglutide point to key missing pieces in Canada's drug approval system.Health Policy | Other paper | 2026 |
| Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.J Enzyme Inhib Med Chem | Other paper | 2026 |
| A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.Scand J Prim Health Care | Other paper | 2026 |
| Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.J Med Econ | Other paper | 2026 |
| Calculating cost per event avoided using a composite number needed to treat.J Med Econ | Other paper | 2026 |
| Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.J Control Release | Other paper | 2026 |
| Cargo-aware design of dissolving microneedles: an FEA-guided rational framework reveals distinct delivery mechanisms for small and large molecules.Int J Pharm | Other paper | 2026 |
| Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance.Pharmacoepidemiol Drug Saf | Other paper | 2026 |
| The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment.Obesity (Silver Spring) | Other paper | 2026 |
| Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.Obesity (Silver Spring) | Other paper | 2026 |
| Adjuvant Glucagon-Like Peptide-1 Receptor Agonist Therapy Post-Bariatric Surgery: An Exploratory Single-Institution Analysis.J Surg Res | Other paper | 2026 |
| GLP-1 receptor agonism in Alzheimer's disease after EVOKE: From single hypothesis to stratified program.J Alzheimers Dis | Other paper | 2026 |
| Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.Diabetes Obes Metab | Other paper | 2026 |
| AI Patient Support and 6-Month Medication Adherence in a Digital Obesity Program: A Retrospective Analysis.Diabetes Obes Metab | Other paper | 2026 |
| Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.Dig Dis Sci | Other paper | 2026 |
| Safety of semaglutide on depressive symptoms among people with HIV in routine clinical care.AIDS | Other paper | 2026 |
| Semaglutide ameliorates traumatic sepsis-induced cardiac injury by activating the March5-ACSL4 axis to suppress ferroptosis.Free Radic Biol Med | Other paper | 2026 |
| A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.Pharmacoeconomics | Other paper | 2026 |
| Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.Br J Clin Pharmacol | Other paper | 2026 |
| LiverPRO Reduces False Positives and Screening Costs Compared With Fibrosis-4 Index in Steatotic Liver Disease.Clin Gastroenterol Hepatol | Other paper | 2026 |
| Activities of daily living and health status benefits of semaglutide in very old patients with heart failure, type 2 diabetes, and obesity: Real-world practice study.Med Clin (Barc) | Other paper | 2026 |
| Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.Lancet Diabetes Endocrinol | Other paper | 2026 |
| Analysis Asks: Are GLP-1 Drugs Safe in People With Frailty?JAMA | Other paper | 2026 |
| Glucagon-Like Peptide-1 Analog-Type Amyloidosis: A Case Report and Review of the Literature.Am J Dermatopathol | Other paper | 2026 |
| Early Treatment Trajectory and Long-Term Persistence to Semaglutide for Obesity: A Population-Based Cohort Study.Diabetes Obes Metab | Other paper | 2026 |
| Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors.Diabetes Res Clin Pract | Other paper | 2026 |
| Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS.Endocrine | Other paper | 2026 |
| Do Preoperative Glucagon-Like Peptide-1 Receptor Agonists Influence Lumbar Fusion Outcomes? A Systematic Review and Meta-Analysis.Int J Spine Surg | Other paper | 2026 |
| Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.Mol Metab | Other paper | 2026 |
| GLP-1 receptor activation attenuates chronic migraine-like behaviour: Sex-specific modulation of opioid- and endocannabinoid-related pathways.Br J Pharmacol | Other paper | 2026 |
| The GLP-1 receptor agonist semaglutide reduces alcohol consumption and anxiety-like behaviors during withdrawal in Marchigian Sardinian alcohol-preferring rats.Neuropharmacology | Other paper | 2026 |
| Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis.Diabetes Care | Other paper | 2026 |
| Oral Health-Related Adverse Events of GLP-1 Receptor Agonists.JDR Clin Trans Res | Other paper | 2026 |
| Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.Diabetes Obes Metab | Other paper | 2026 |
| Glucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study.Transplantation | Other paper | 2026 |
| Semaglutide Demonstrates Benefits Across Frailty Levels.JAMA | Other paper | 2026 |
| [Efficacy and safety of domestic semaglutide injection in patients with type 2 diabetes mellitus inadequately controlled with metformin: a multicenter, randomized, controlled phase 3 equivalence clinical trial].Zhonghua Yi Xue Za Zhi | Other paper | 2026 |
| Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis.Heart Rhythm | Other paper | 2026 |
| UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial.Cell Metab | Other paper | 2026 |
| GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis.Breast Cancer Res Treat | Other paper | 2026 |
| Impact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time Series.Diabetes Obes Metab | Other paper | 2026 |